

SEQUENCE LISTING

| | KISHIMOTO, TADAMITSU MIHARA, MASAHIKO MORIYA, YOICHIRO OSHUGI, YOSIYUKI | |
|---------------------------|--|----|
| | CHRONIC RHEUMATOID ARTHRITIS THERAPY CONTAINING IL-6 ANTAGONIST AS EFFECTIVE COMPONENT | |
| <130> | 053466/0296 | |
| | 09/756,125 2001-01-09 | |
| | 09/233,474 1999-01-20 | |
| | 08/817,084 1997-04-07 | |
| | PCT/JP95/01144 1995-06-07 | |
| | 08/971,997 1997-02-21 | |
| | 08/268,520 1994-06-30 | |
| | JP 6-244035 1994-10-07 | |
| <160> | 20 | |
| <170> | PatentIn Ver. 2.1 | |
| <210><211><212><212><213> | 20 | |
| <220> <223> | Description of Artificial Sequence: Synthetic oligonucletide | |
| <400> atattc | 1 Etcta gagagattet | 20 |
| <210><211><212><212><213> | 11 | |
| <400> Arg Al | 2 a Ser Gln Asp Ile Ser Ser Tyr Leu Asn 5 10 | |

```
<210> 3
<211> 7
<212> PRT
<213> Homo sapiens
<400> 3
Tyr Thr Ser Arg Leu His Ser
1
<210> 4
<211> 9
<212> PRT
<213> Homo sapiens
<400> 4
Gln Gln Gly Asn Thr Leu Pro Tyr Thr
                5
<210> 5
<211> 23
<212> PRT
<213> Homo sapiens
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
                5
                                     10
Asp Arg Val Thr Ile Thr Cys
           20
<210> 6
<211> 15
<212> PRT
<213> Homo sapiens
<400> 6
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
<210> 7
<211> 32
<212> PRT
<213> Homo sapiens
<400> 7
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
<210> 8
<211> 10
```

<212> PRT

```
<213> Homo sapiens
<400> 8
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                 5
<210> 9
<211> 32
<212> PRT
<213> Homo sapiens
<400> 9
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
                  5
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
                                 25
<210> 10
<211> 6
<212> PRT
<213> Homo sapiens
<400> 10
Ser Asp His Ala Trp Ser
<210> 11
<211> 16
<212> PRT
<213> Homo sapiens
<400> 11
Tyr Ile Ser Tyr Ser Gly Ile Thr Thr Tyr Asn Pro Ser Leu Lys Ser
1 5
                                    10
<210> 12
<211> 10
<212> PRT
<213> Homo sapiens
<400> 12
Ser Leu Ala Arg Thr Thr Ala Met Asp Tyr
<210> 13
<211> 30
<212> PRT
<213> Homo sapiens
<400> 13
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln
```

```
20
                                  25
<210> 14
<211> 14
<212> PRT
<213> Homo sapiens
<400> 14
Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly
                  5
<210> 15
<211> 32
<212> PRT
<213> Homo sapiens
<400> 15
Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg
Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg
             20
                                  25
<210> 16
<211> 11
<212> PRT
<213> Homo sapiens
<400> 16
Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser
                5
<210> 17
<211> 438
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic construct
<220>
<221> CDS
<222> (12)..(425)
<220>
<221> sig_peptide
<222> (12)..(68)
<220>
<221> sig_peptide
```

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr

<222> (69)..(425)

| • | • | • | • | | | | | | | | | |
|----------------------------|---|---|-------------------|-------|---|--|---|----|-----|-------|----------------|-----|
| 0> 1 ⁷ cttco | | | | _ | _ | | | - | | _ | a aca a Thr | 50 |
| | | 1 | - | • | 5 | | | 10 | | | | |
| | | | cac His | | | | | | | | | 98 |
| | | | agc Ser | | | | | | | | | 146 |
| | | | agc Ser 50 | | | | | | | | | 194 |
| _ | | | gag Glu | | | | - | - | | | | 242 |
| | | | tct Ser | | | | | _ | _ | _ | | 290 |
| | | | ttc Phe | | | | | | | | | 338 |
| | | | tat Tyr | | | | | | | | | 386 |
| | | | caa Gln 130 | | | | | | ggt | gagto | gga | 435 |

438

<210> 18

tcc

<211> 138

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic construct

<400> 18

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 \cdot

Val His Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg 20 25 30

Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile

35 40 45

Thr Ser Asp His Ala Trp Ser Trp Val Arg Gln Pro Pro Gly Arg Gly 50 55 Leu Glu Trp Ile Gly Tyr Ile Ser Tyr Ser Gly Ile Thr Thr Tyr Asn 70 75 Pro Ser Leu Lys Ser Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn 85 Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val 105 Tyr Tyr Cys Ala Arg Ser Leu Ala Arg Thr Thr Ala Met Asp Tyr Trp 115 Gly Gln Gly Ser Leu Val Thr Val Ser Ser 135 <210> 19 <211> 402 <212> DNA <213> Artificial Sequence <223> Description of Artificial Sequence: Synthetic construct <220> <221> CDS <222> (12)..(389) <220> <221> sig_peptide <222> (12)..(68) <220> <221> mat_peptide <222> (69)..(389) aagettecae e atg gga tgg age tgt ate ate ete tte ttg gta gea aca 50 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr -15 gct aca ggt gtc cac tcc gac atc cag atg acc cag agc cca agc agc 98 Ala Thr Gly Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser -1 1 ctg agc gcc agc gtg ggt gac aga gtg acc atc acc tgt aga gcc agc 146 Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser 15 20

| cag gac atc a Gln Asp Ile S 3 | | | | | | | | | 194 |
|---|---|---|--------------------------------------|---|---|--------------------------|--------------------------------|--------------------------------|-----|
| gct cca aag c Ala Pro Lys L 45 | | | yr Thr | | | | | | 242 |
| cca agc aga t Pro Ser Arg P 60 | | | | | | | | | 290 |
| atc agc agc c Ile Ser Ser L 75 | _ | | | - | | _ | | _ | 338 |
| ggt aac acg c Gly Asn Thr L | | _ | | | _ | | _ | | 386 |
| aaa cgtgagtgg Lys | a tcc | | | | | | | | 402 |
| <210> 20 <211> 126 <212> PRT <213> Artific | ial Seque | nce | | | | | | | |
| | | | | | | | | | |
| <220> <223> Descrip | tion of A | rtificia | al Sequ | lence: Sy | /nthetic | cons | struc | ct | |
| | | | | | | | | | |
| <223> Descrip <400> 20 | er Cys Il -15 .sp Ile Gl | e Ile Le | eu Phe | Leu Val | Ala Thr | Ala | Thr -5 | Gly | |
| <223> Descrip <400> 20 Met Gly Trp S Val His Ser A | er Cys Il -15 .sp Ile Gl | e Ile Le n Met Th 5 | eu Phe | Leu Val -10 Ser Pro | Ala Thr Ser Ser 10 | Ala Leu | Thr -5 Ser | Gly Ala | |
| <223> Descrip <400> 20 Met Gly Trp S Val His Ser A -1 1 Ser Val Gly A | er Cys Il -15 .sp Ile Gl | e Ile Le n Met Th 5 1 Thr II | eu Phe nr Gln le Thr | Leu Val -10 Ser Pro Cys Arg | Ala Thr Ser Ser 10 Ala Ser 25 | Ala Leu Gln | Thr -5 Ser | Gly Ala Ile | |
| <223> Descrip <400> 20 Met Gly Trp S Val His Ser A -1 1 Ser Val Gly A 15 Ser Ser Tyr L | er Cys Il -15 sp Ile Gl sp Arg Va | e Ile Len Met Th 5 1 Thr II 20 | eu Phe nr Gln le Thr | Leu Val -10 Ser Pro Cys Arg Lys Pro 40 | Ala Thr Ser Ser 10 Ala Ser 25 Gly Lys | Ala Leu Gln | Thr -5 Ser Asp | Gly Ala Ile Lys 45 | |
| <pre><223> Descrip <400> 20 Met Gly Trp S Val His Ser A</pre> | er Cys II -15 sp Ile Gl sp Arg Va eu Asn Tr 35 yr Tyr Th 50 | e Ile Le | eu Phe nr Gln le Thr ln Gln | Leu Val -10 Ser Pro Cys Arg Lys Pro 40 His Ser 55 | Ala Thr Ser Ser 10 Ala Ser 25 Gly Lys Gly Val | Ala Leu Gln Ala | Thr -5 Ser Asp Pro | Gly Ala Ile Lys 45 | |

Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 95 $\,$ 100 $\,$ 105 $\,$